Etodolac osmotic pump type controlled-release preparation and preparation thereof

Abstract

The invention belongs to the pharmaceutical preparation field and discloses an osmotic pump type controlled release preparation of etodolac and a preparation method thereof. An osmotic pump tablet comprises a tablet core and a controlled release semipermeable coating film that is coated outside the tablet core and with a hole for releasing drug. The tablet core comprises materials by following weight percentage: 60.9 to 65.5 percent of etodolac, 27.1 to 31.2 percent of osmotic pressure active material, 5.5 to 8.0 percent of an auxiliary material that can ensure the basic remedy to be released easily and the rest is other auxiliary materials. The osmotic pump controlled release semipermeable coating film comprises by materials by following weight percentage: 71.4 to 76.9 percent of semipermeable high molecular coating material and 23.1 to 28.6 percent of pore-forming agent. The manners of pore-forming include a mechanical drilling and a laser boring. By adjusting the prescription of the tablet core and the coating film in the invention, the speed of constant release of drug can be effectively regulated so as to obtain a steadier, lasting and effective blood concentration, thus reducing the side effect of drug and times of dosage, and promoting the compliance of a sufferer. The osmotic pump type controlled release preparation of etodolac of the invention can be widely used for treating diseases like rheumatoid arthritis, arthritis deformans and osteoarthritisetc.

Description

technical field

[0001] The invention belongs to the technical field of pharmaceutical preparations, and relates to an etodolac osmotic pump type controlled release preparation and a preparation method thereof. Background technique

[0002] Etodolac is a potent non-steroidal anti-inflammatory drug (NSAIDs) synthesized in the 1960s, which differs from other NSAIDs in that it has a tetrahydropyranyl ring , are pyrancarboxylic acid NSAIDs. Etodolac is a new generation of cyclooxygenase-2 (COX-2) highly selective inhibitor, its advantage is that it has high and suitable COX-2 selectivity, and has little effect on COX-1 within the therapeutic dose , which protects the gastrointestinal mucosa while exerting a potent anti-inflammatory effect; its other advantage lies in the protective effect on human chondrocytes, and the in vitro study of Henrotin Y provides evidence that etodolac maintains cartilage integrity under inflammatory conditions . Etodolac is approved to control the s...

Images